Glucotrack, Inc. (NASDAQ: GCTK) issued a shareholder update on September 23, 2026, providing details on the strategic direction of its subsidiary, Lokahi Therapeutics. The update, furnished as Exhibit 99.1 to the Form 8-K, outlines the company’s focus on acquiring and monetizing differentiated therapeutic assets while continuing to operate its Glucotrack Technologies subsidiary, which develops continuous blood glucose monitoring technology.
CEO Erik Emerson stated that the company has sharpened its focus on building a clinical-stage biopharmaceutical company capable of discovering, advancing, and monetizing healthcare opportunities. The company has completed a strategic business combination and is currently working through post-closing matters, including the conversion of Series A convertible preferred stock, which remains subject to Nasdaq requirements.
The primary focus for Lokahi Therapeutics is the LT-100 development program, a biologic designed for the treatment of osteoarthritis knee pain. The company has submitted a clinical protocol for regulatory review and is targeting study initiation in the near term. The planned study will evaluate the safety and efficacy of LT-100 administered via subcutaneous injection on a once-weekly basis, comparing it to the historical regimen of 15 weekly intradermal injections.
In addition to LT-100, the company highlighted the expansion of its ai² platform. The platform consists of three components: ai² Pipeline, which identifies opportunities through a network of over 14 university partners; ai² Talent, which fosters emerging talent; and ai² Accelerator, which supports emerging technology initiatives. The ai² Pipeline has identified over 45 assets that met initial screening criteria in its first year, and the company is engaged in preliminary business development discussions regarding these opportunities.
The company also mentioned Qare, an emerging initiative being developed within the Accelerator framework. The update emphasizes a business model focused on discovering near-term, value-creating therapeutics, advancing them through process enhancements, and monetizing assets before the completion of registration trials.
